|
1
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marcucci F, Stassi G and De Maria R:
Epithelial-mesenchymal transition: A new target in anticancer drug
discovery. Nat Rev Drug Discov. 15:311–325. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chaffer CL, San Juan BP, Lim E and
Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis
Rev. 35:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Andreasen PA, Egelund R and Petersen HH:
The plasminogen activation system in tumor growth, invasion, and
metastasis. Cell Mol Life Sci. 57:25–40. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pavón MA, Arroyo-Solera I, Céspedes MV,
Casanova I, León X and Mangues R: uPA/uPAR and SERPINE1 in head and
neck cancer: Role in tumor resistance, metastasis, prognosis and
therapy. Oncotarget. 7:57351–57366. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pedersen H, Brünner N, Francis D,
Osterlind K, Rønne E, Hansen HH, Danø K and Grøndahl-Hansen J:
Prognostic impact of urokinase, urokinase receptor, and type 1
plasminogen activator inhibitor in squamous and large cell lung
cancer tissue. Cancer Res. 54:4671–4675. 1994.PubMed/NCBI
|
|
8
|
Lin X, Lin BW, Chen XL, Zhang BL, Xiao XJ,
Shi JS, Lin JD and Chen X: PAI-1/PIAS3/Stat3/miR-34a forms a
positive feedback loop to promote EMT-mediated metastasis through
Stat3 signaling in Non-small cell lung cancer. Biochem Biophys Res
Commun. 493:1464–1470. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hirahata M, Osaki M, Kanda Y, Sugimoto Y,
Yoshioka Y, Kosaka N, Takeshita F, Fujiwara T, Kawai A, Ito H, et
al: PAI-1, a target gene of miR-143, regulates invasion and
metastasis by upregulating MMP-13 expression of human osteosarcoma.
Cancer Med. 5:892–902. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seker F, Cingoz A, Sur-Erdem İ, Erguder N,
Erkent A, Uyulur F, Esai Selvan M, Gümüş ZH, Gönen M, Bayraktar H,
et al: Identification of SERPINE1 as a regulator of glioblastoma
cell dispersal with transcriptome profiling. Cancers (Basel).
11:112019. View Article : Google Scholar
|
|
11
|
Pavón MA, Arroyo-Solera I, Téllez-Gabriel
M, León X, Virós D, López M, Gallardo A, Céspedes MV, Casanova I,
López-Pousa A, et al: Enhanced cell migration and apoptosis
resistance may underlie the association between high SERPINE1
expression and poor outcome in head and neck carcinoma patients.
Oncotarget. 6:29016–29033. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kubala MH and DeClerck YA: The plasminogen
activator inhibitor-1 paradox in cancer: A mechanistic
understanding. Cancer Metastasis Rev. 38:483–492. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gerwin BI, Keski-Oja J, Seddon M, Lechner
JF and Harris CC: TGF-beta 1 modulation of urokinase and PAI-1
expression in human bronchial epithelial cells. Am J Physiol.
259:L262–L269. 1990.PubMed/NCBI
|
|
14
|
Kortlever RM, Higgins PJ and Bernards R:
Plasminogen activator inhibitor-1 is a critical downstream target
of p53 in the induction of replicative senescence. Nat Cell Biol.
8:877–884. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kawarada Y, Inoue Y, Kawasaki F, Fukuura
K, Sato K, Tanaka T, Itoh Y and Hayashi H: TGF-β induces p53/Smads
complex formation in the PAI-1 promoter to activate transcription.
Sci Rep. 6:354832016. View Article : Google Scholar
|
|
16
|
Samarakoon R and Higgins PJ: Integration
of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen
activator inhibitor type-1 gene expression in vascular smooth
muscle cells. Thromb Haemost. 100:976–983. 2008. View Article : Google Scholar
|
|
17
|
Higgins SP, Tang Y, Higgins CE, Mian B,
Zhang W, Czekay RP, Samarakoon R, Conti DJ and Higgins PJ:
TGF-β1/p53 signaling in renal fibrogenesis. Cell Signal. 43:1–10.
2018. View Article : Google Scholar
|
|
18
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lei QY, Zhang H, Zhao B, Zha ZY, Bai F,
Pei XH, Zhao S, Xiong Y and Guan KL: TAZ promotes cell
proliferation and epithelial-mesenchymal transition and is
inhibited by the hippo pathway. Mol Cell Biol. 28:2426–2436. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Liu J, Ying X, Lin PC and Zhou BP:
Twist-mediated epithelial-mesenchymal transition promotes breast
tumor cell invasion via inhibition of Hippo pathway. Sci Rep.
6:246062016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lamar JM, Stern P, Liu H, Schindler JW,
Jiang ZG and Hynes RO: The Hippo pathway target, YAP, promotes
metastasis through its TEAD-interaction domain. Proc Natl Acad Sci
USA. 109:E2441–E2450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dupont S, Morsut L, Aragona M, Enzo E,
Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M,
Bicciato S, et al: Role of YAP/TAZ in mechanotransduction. Nature.
474:179–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sebio A and Lenz HJ: Molecular pathways:
Hippo signaling, a critical tumor suppressor. Clin Cancer Res.
21:5002–5007. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Varelas X, Sakuma R, Samavarchi-Tehrani P,
Peerani R, Rao BM, Dembowy J, Yaffe MB, Zandstra PW and Wrana JL:
TAZ controls Smad nucleocytoplasmic shuttling and regulates human
embryonic stem-cell self-renewal. Nat Cell Biol. 10:837–848. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grannas K, Arngården L, Lönn P,
Mazurkiewicz M, Blokzijl A, Zieba A and Söderberg O: Crosstalk
between Hippo and TGFβ: subcellular localization of YAP/TAZ/Smad
complexes. J Mol Biol. 427:3407–3415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Szeto SG, Narimatsu M, Lu M, He X, Sidiqi
AM, Tolosa MF, Chan L, De Freitas K, Bialik JF, Majumder S, et al:
YAP/TAZ Are mechanoregulators of TGF-β-Smad signaling and renal
fibrogenesis. J Am Soc Nephrol. 27:3117–3128. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bae GY, Hong SK, Park JR, Kwon OS, Kim KT,
Koo J, Oh E and Cha HJ: Chronic TGFβ stimulation promotes the
metastatic potential of lung cancer cells by Snail protein
stabilization through integrin β3-Akt-GSK3β signaling. Oncotarget.
7:25366–25376. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
30
|
Kwon OS, Lee H, Kong HJ, Kwon EJ, Park JE,
Lee W, Kang S, Kim M, Kim W and Cha HJ: Connectivity map-based drug
repositioning of bortezomib to reverse the metastatic effect of
GALNT14 in lung cancer. Oncogene. 39:4567–4580. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dupont S: Luciferase reporter assays to
determine YAP/TAZ activity in mammalian cells. Methods Mol Biol.
1893:121–135. 2019. View Article : Google Scholar
|
|
32
|
Vinci M, Box C and Eccles SA:
Three-dimensional (3D) tumor spheroid invasion assay. J Vis Exp.
May 1–2015.Epub ahead of print. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bae GY, Choi SJ, Lee JS, Jo J, Lee J, Kim
J and Cha HJ: Loss of E-cadherin activates EGFR-MEK/ERK signaling,
which promotes invasion via the ZEB1/MMP2 axis in non-small cell
lung cancer. Oncotarget. 4:2512–2522. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kwon OS, Kwon EJ, Kong HJ, Choi JY, Kim
YJ, Lee EW, Kim W, Lee H and Cha HJ: Systematic identification of a
nuclear receptor-enriched predictive signature for erastin-induced
ferroptosis. Redox Biol. 37:1017192020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Katsuno Y, Meyer DS, Zhang Z, Shokat KM,
Akhurst RJ, Miyazono K and Derynck R: Chronic TGF-β exposure drives
stabilized EMT, tumor stemness, and cancer drug resistance with
vulnerability to bitopic mTOR inhibition. Sci Signal. 12:122019.
View Article : Google Scholar
|
|
37
|
Hong SK, Park JR, Kwon OS, Kim KT, Bae GY
and Cha HJ: Induction of integrin β3 by sustained ERK activity
promotes the invasiveness of TGFβ-induced mesenchymal tumor cells.
Cancer Lett. 376:339–346. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kwon OS, Hong SK, Kwon SJ, Go YH, Oh E and
Cha HJ: BCL2 induced by LAMTOR3/MAPK is a druggable target of
chemo-radioresistance in mesenchymal lung cancer. Cancer Lett.
403:48–58. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hong SK, Lee H, Kwon OS, Song NY, Lee HJ,
Kang S, Kim JH, Kim M, Kim W and Cha HJ: Large-scale
pharmacogenomics based drug discovery for ITGB3 dependent
chemoresistance in mesenchymal lung cancer. Mol Cancer. 17:1752018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ghandi M, Huang FW, Jané-Valbuena J,
Kryukov GV, Lo CC, McDonald ER III, Barretina J, Gelfand ET,
Bielski CM, Li H, et al: Next-generation characterization of the
Cancer Cell Line Encyclopedia. Nature. 569:503–508. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Klein RM, Bernstein D, Higgins SP, Higgins
CE and Higgins PJ: SERPINE1 expression discriminates site-specific
metastasis in human melanoma. Exp Dermatol. 21:551–554. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Arroyo-Solera I, Pavón MA, León X, López
M, Gallardo A, Céspedes MV, Casanova I, Pallarès V, López-Pousa A,
Mangues MA, et al: Effect of serpinE1 overexpression on the primary
tumor and lymph node, and lung metastases in head and neck squamous
cell carcinoma. Head Neck. 41:429–439. 2019.
|
|
43
|
Yang JD, Ma L and Zhu Z: SERPINE1 as a
cancer-promoting gene in gastric adenocarcinoma: Facilitates tumour
cell proliferation, migration, and invasion by regulating EMT. J
Chemother. 31:408–418. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu
J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates
YAP-dependent gene induction and growth control. Genes Dev.
22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Moroishi T, Park HW, Qin B, Chen Q, Meng
Z, Plouffe SW, Taniguchi K, Yu FX, Karin M, Pan D, et al: A
YAP/TAZ-induced feedback mechanism regulates Hippo pathway
homeostasis. Genes Dev. 29:1271–1284. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wada K, Itoga K, Okano T, Yonemura S and
Sasaki H: Hippo pathway regulation by cell morphology and stress
fibers. Development. 138:3907–3914. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kutz SM, Hordines J, McKeown-Longo PJ and
Higgins PJ: TGF-beta1-induced PAI-1 gene expression requires MEK
activity and cell-to-substrate adhesion. J Cell Sci. 114:3905–3914.
2001.PubMed/NCBI
|
|
48
|
Dennler S, Itoh S, Vivien D, ten Dijke P,
Huet S and Gauthier JM: Direct binding of Smad3 and Smad4 to
critical TGF beta-inducible elements in the promoter of human
plasminogen activator inhibitor-type 1 gene. EMBO J. 17:3091–3100.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xu B, Bai Z, Yin J and Zhang Z: Global
transcriptomic analysis identifies SERPINE1 as a prognostic
biomarker associated with epithelial-to-mesenchymal transition in
gastric cancer. PeerJ. 7:e70912019. View Article : Google Scholar :
|
|
50
|
Hirashima Y, Kobayashi H, Suzuki M, Tanaka
Y, Kanayama N and Terao T: Transforming growth factor-beta1
produced by ovarian cancer cell line HRA stimulates attachment and
invasion through an up-regulation of plasminogen activator
inhibitor type-1 in human peritoneal mesothelial cells. J Biol
Chem. 278:26793–26802. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Allan EH, Zeheb R, Gelehrter TD, Heaton
JH, Fukumoto S, Yee JA and Martin TJ: Transforming growth factor
beta inhibits plasminogen activator (PA) activity and stimulates
production of urokinase-type PA, PA inhibitor-1 mRNA, and protein
in rat osteoblast-like cells. J Cell Physiol. 149:34–43. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Higgins CE, Tang J, Mian BM, Higgins SP,
Gifford CC, Conti DJ, Meldrum KK, Samarakoon R and Higgins PJ:
TGF-β1-p53 cooperativity regulates a profibrotic genomic program in
the kidney: Molecular mechanisms and clinical implications. FASEB
J. 33:10596–10606. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Samarakoon R, Higgins SP, Higgins CE and
Higgins PJ: The TGF-β1/p53/PAI-1 signaling axis in vascular
senescence: Role of caveolin-1. Biomolecules. 9:92019. View Article : Google Scholar
|
|
54
|
Andreasen PA, Kjøller L, Christensen L and
Duffy MJ: The urokinase-type plasminogen activator system in cancer
metastasis: A review. Int J Cancer. 72:1–22. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ghosh AK, Rai R, Park KE, Eren M, Miyata
T, Wilsbacher LD and Vaughan DE: A small molecule inhibitor of
PAI-1 protects against doxorubicin-induced cellular senescence.
Oncotarget. 7:72443–72457. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kang J, Kim W, Kwon T, Youn H, Kim JS and
Youn B: Plasminogen activator inhibitor-1 enhances radioresistance
and aggressiveness of non-small cell lung cancer cells. Oncotarget.
7:23961–23974. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Moroishi T, Hansen CG and Guan KL: The
emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 15:73–79.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fujii M, Toyoda T, Nakanishi H, Yatabe Y,
Sato A, Matsudaira Y, Ito H, Murakami H, Kondo Y, Kondo E, et al:
TGF-β synergizes with defects in the Hippo pathway to stimulate
human malignant mesothelioma growth. J Exp Med. 209:479–494. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Uchiyama T, Okajima F, Mogi C, Tobo A,
Tomono S and Sato K: Alamandine reduces leptin expression through
the c-Src/p38 MAP kinase pathway in adipose tissue. PLoS One.
12:e01787692017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Li C, Zhu HY, Bai WD, Su LL, Liu JQ, Cai
WX, Zhao B, Gao JX, Han SC, Li J, et al: MiR-10a and miR-181c
regulate collagen type I generation in hypertrophic scars by
targeting PAI-1 and uPA. FEBS Lett. 589:380–389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kwon OS, Kim W, Cha HJ and Lee H: In
silico drug repositioning: From large-scale transcriptome data to
therapeutics. Arch Pharm Res. 42:879–889. 2019. View Article : Google Scholar : PubMed/NCBI
|
